Researchers in the College of Design and Engineering (CDE) at the National University of Singapore and the National Cancer Centre Singapore (NCCS) have developed a hydrogel-based platform that extends the survival of patient-derived tumour tissues in the lab. The platform better replicates the tumour’s natural environment, allowing for more accurate evaluation of cancer drugs - particularly for peritoneal metastases, an advanced stage for abdominal and pelvic cancers. The study, published in Advanced Materials, could pave the way for more personalised and effective treatment strategies.

Amplification-free, highly sensitive, and specific nucleic acid detection is crucial for health monitoring and diagnosis. The type III CRISPR-Cas10 system, which provides viral immunity through CRISPR-associated protein effectors, enables a new amplification-free nucleic acid diagnostic tool. In this study, we develop a CRISPR-graphene field-effect transistors (GFETs) biosensor by combining the type III CRISPR-Cas10 system with GFETs for direct nucleic acid detection. This biosensor exploits the target RNA-activated continuous ssDNA cleavage activity of the dCsm3 CRISPR-Cas10 effector and the high charge density of a hairpin DNA reporter on the GFET channel to achieve label-free, amplification-free, highly sensitive, and specific RNA detection. The CRISPR-GFET biosensor exhibits excellent performance in detecting medium-length RNAs and miRNAs, with detection limits at the aM level and a broad linear range of 10^-15 to 10^-11 M for RNAs and 10^-15 to 10^-9 M for miRNAs. It shows high sensitivity in throat swabs and serum samples, distinguishing between healthy individuals (N = 5) and breast cancer patients (N = 6) without the need for extraction, purification, or amplification. This platform mitigates risks associated with nucleic acid amplification and cross-contamination, making it a versatile and scalable diagnostic tool for molecular diagnostics in human health.